Immunotherapy of Cancer
Major scientific advances in molecular and clinical immunology have produced tremendous growth in our understanding of how cancer is recognized by the immune system, as well as in our ability to control and modulate that recognition. In Immunotherapy of Cancer, expert bench and clinical scientists j...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Totowa, NJ :
Humana Press,
2006.
|
| Σειρά: | Cancer Drug Discovery and Development
|
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Discovery of Target Molecules for Cancer Immunotherapy by Genetic and Bioinformatic Approaches
- Current Strategies for the Identification of Immunogenic Epitopes of Tumor Antigens
- Current and Future Role of Natural-Killer Cells in Cancer Immunotherapy
- The Role of Immune Monitoring in Evaluating Cancer Immunotherapy
- Statistical Analysis of Immune Response Assays in Cancer Immunotherapy Trials
- DNA Vaccines for Cancer Immunotherapy
- Dendritic Cells
- Different Approaches to Dendritic Cell-Based Cancer Immunotherapy
- Anti-Idiotype Antibody Vaccines for the Immunotherapy of Cancer
- Autologous Tumor-Derived Heat Shock Protein Vaccine as a New Paradigm for Individualized Cancer Therapeutics
- Tumor-Reactive T-Cells for Adoptive Immunotherapy
- T-Cell Adoptive Immunotherapy of Cancer
- Retroviral-Mediated Gene Transfer for Engineering Tumor-Reactive T-Cells
- Harnessing the Potential of Graft-vs-Tumor
- Tumor-Induced Immune Suppression and Immune Escape
- The Tumor Microenvironment
- Manipulation of Lymphocyte Homeostasis for Enhancing Antitumor Immunity
- Fast-Lane Evolution in the Tumor Microenvironment
- Manipulating Immunological Checkpoints to Maximize Antitumor Immunity
- Interleukin-2 as Cancer Therapy
- Biological and Clinical Properties of the Type 1 Interferons
- Promising ?-Chain Cytokines for Cancer Immunotherapy
- The Therapeutic Use of Natural-Killer Cells in Hematological Malignancies
- Antibody Therapy for Solid Tumors
- Antibody Therapy for Non-Hodgkin’s Lymphoma
- Approaches to In Vivo Imaging of Cancer Immunotherapy
- Design Issues for Early-Stage Clinical Trials for Cancer Vaccines
- Monoclonal Antibody Therapy of Cancer.
